Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients

Blood Adv. 2021 Apr 27;5(8):2272-2278. doi: 10.1182/bloodadvances.2020003976.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Mutation
  • Myelodysplastic Syndromes* / diagnosis
  • Myelodysplastic Syndromes* / genetics
  • Prognosis
  • Risk